Introduction
Erythrokeratodermia is a group of inherited disorders characterized by well-demarcated erythematous lesions and hyperkeratotic plaques. Connexin mutations have been demonstrated to be responsible for most cases of erythrokeratodermia variabilis (EKV). In this condition, we usually observe migratory red patches along with fixed localized or generalized keratotic plaques. Erythrokeratodermia variabilis was also known as Mendes da Costa syndrome.[1] Later, clinical features of progressive symmetric erythrokeratodermia (PSEK), which is known to induce stationary erythematous progressive plaques, were observed within a single family association with EKV features.[2] Therefore, the thinking became that the two diseases (EKV and PSEK) were different manifestations of a single inherited clinical entity. And with the identification of the same gene mutation in patients with EKV and PSEK, some authors proposed the designation of erythrokeratodermia variabilis progressiva (EKVP) to encompass the diversity of the clinical phenotypes of both EKV and PSEK.[3]
Etiology
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Erythrokeratodermia variabilis demonstrates heterozygous dominant inheritance. EKV-associated mutations are usually located in genes encoding either Cx31 (GJB3) or Cx30.3 (GJB4) and occasionally Cx43 (GJA1).[4] These proteins (connexin 31, connexin 30.3, and connexin 43) are gap junction proteins that belong to a large family of transmembrane proteins forming intercellular channels. Gap junctions are responsible for the exchange of metabolites, ions, and secondary messengers between cells. The connexin family in humans consists of at least 20 distinct proteins, and most cell types and tissues express more than one connexin gene.[5] Connexin 31 expresses in the skin, peripheral nerves, and the cochlea.[6] Cx30.3 expresses in the skin, kidney, and preimplantation blastocyst.[7] Cx43 is ubiquitously expressed.[8] All reported mutations in EKV are non-conservative amino acid substitution mutations, resulting in impaired epidermal differentiation.
There are reports of rare forms inherited with autosomal recessive modality caused by homozygous mutations in GJB3 that were also described in patients with EKV, although EKV is admittedly a consequence of connexin mutations.[9][10] Cases with typical features of EKV were not associated with this group of mutations.[11]
In a study by Common et al., molecular investigations of GJB3 and GJB4 were performed in five pedigrees and three sporadic cases of EKV. The detection of connexin 31(Cx31) or connexin 30.3 (Cx30.3) mutations was in only three probands, of which two were novel mutations, and one was a recurrent mutation. Also, no mutations in these patients were detected in other epidermal disease-associated Cx genes. The authors conclude that EKV is a heterogeneous condition, and individuals clinically diagnosed with this disease harbor different Cx31 or Cx30.3 mutations.[12]
Epidemiology
Erythrokeratodermia variabilis lesions are usually present in the first year of life and less frequently since birth.[13] More rarely, EKV occurs later in childhood and even in early adult life.[14] It is a rare disorder, predominantly transmitted in an autosomal dominant manner.[4] The disease shows nearly complete penetrance but with considerable variability. There is documentation of a few cases of autosomal recessive inheritance.
Histopathology
Histopathological examination shows only non-specific findings, including papillomatosis, moderate to severe acanthosis, hypergranulosis composed of two to four layer cells, compact hyperkeratosis or parakeratosis, and follicular plugging. In the papillary dermis, there are dilated, elongated capillaries with a variable perivascular inflammatory infiltrate.[2] An aspect of suprapapillary thinning is a possible presenting sign, and when it is associated with severe papillomatosis, this may result in a “church spire” configuration of the epidermis. Ultrastructural studies show a decreased number of lamellar bodies in the granular layer.[15]
History and Physical
There are two characteristic types of lesions:
- Transient erythematous patches
- Stable hyperkeratotic plaques
Usually, one of these two features predominates, and occasionally one is missing. Migratory-shaped red areas are the initial presenting sign. These lesions are usually well-demarcated with a map-like or annular appearance. They can coalesce into large figurate patches, which vary in shape, size, number, and position over minutes, hours, or, more often, days.[1] A blanched halo may also surround the plaques. Emotional stress, environmental heat or cold, mechanical friction, and sun exposure may cause more prominent erythematous lesions.[16] Stable hyperkeratotic plaques with scaling of the skin evolve simultaneously with or following the development of migratory red patches. These former lesions are usually well-demarcated, yellow to brown, and often on a red basis. They are thickened plaques exhibiting a geographic morphology. Sometimes it is so thick and dark that it manifests as a hystrix-like appearance. Moreover, hypertrichosis may present as well as a collarette-like peeling or psoriasiform scales.
Some atypical features of the disease are thought to be a probable clinical variant of EKV. That includes lesions resembling erythema gyratum repens,[17] with a mutation in the Cx30.3 gene identified in these families. Erythrokeratodermia en cocarde is made of circinate or gyrate erythematous patches and has correlations with mutations in GJB4.[18] Some other cases present with erythema annulare centrifugum-like lesions.[1]
The lesions of EKV have a predilection for the extensor aspects of the limbs, buttocks, and lateral trunk in an almost symmetric distribution.[5] In half of all patients, the thickening of the skin extends onto the palms and soles, resulting in palmoplantar keratoderma. Face, scalp, and flexures tend to be spared, but any part of the skin surface may be involved.[1] Skin appendages, like hair, teeth, and nails, are unaffected by this disease, and their growth and development progress normally.
Symptoms like a burning sensation in erythematous lesions may cause discomfort in some patients.[16] EKV tends to stabilize after puberty. However, the duration of the overall condition is lifelong, but an improvement over time and periodic clearing of the skin is also possible.
Evaluation
Erythrokeratodermia variabilis is mostly a skin-limited condition. Nevertheless, the evaluation of systemic manifestations is necessary to eliminate other variants of erythrokeratodermia that can mimic EKV clinically. These include KID syndrome with erythrokeratodermia-like lesions. In this condition, keratitis, hearing loss, alopecia, and increased susceptibility to infection are present. Moreover, reports exist of neurological symptoms in association with EKV-like lesions including ataxia, and peripheral neuropathy.[1]
Treatment / Management
Therapy is almost symptomatic and depends on the severity and extent of the hyperkeratosis. Topical management is indicated in mild forms include emollients, topical retinoids, and keratolytic. Systemic retinoids with doses considerably lower compared with those required for other disorders of cornification may be beneficial in some extensive and severe forms.[19] These agents often cause a remarkable improvement and, in some cases, a complete clearing of the hyperkeratosis. Retinoids show a lower response in relieving erythematous lesions. This latter often results in cosmetic concerns, which may require by using camouflage makeup. Patients should ideally avoid sudden temperature changes, friction, and irritation.(B3)
Recently, novel therapies targeting connexin hemichannels and gap junctions with a direct inhibitory action are being studied and may become available in the future.[4]
Differential Diagnosis
Although lesions in erythrokeratodermia variabilis may closely resemble in early stages those of urticaria, differentiating factors include the longer duration of the disease and the occasional presence of scales.[1] When fixed plaques, psoriasis is distinguished by histopathological examination.
In Netherton syndrome, ichthyosis demonstrates migratory and serpiginous red plaques that are typical with double-edged scaly borders, and patients usually have other manifestations, including hair shaft abnormalities, eczematous lesions, and pruritus. Differential diagnosis also includes different rare types of ichthyosis such as erythrokeratolysis hiemalis, epidermolytic ichthyosis due to KRT1 and KRT10 mutations, and Greither syndrome.
Prognosis
Except for the aesthetic prognosis, erythrokeratodermia variabilis is a benign affection with no extracutaneous manifestations.
Enhancing Healthcare Team Outcomes
Erythrokeratodermia variabilis is a genetically determined condition that can easily be confused with more common dermatoses like psoriasis or urticaria. Pediatricians, as well as dermatologists, primary care physicians, and nurse practitioners, and nurses with specialty training in dermatology should be aware of this condition to provide genetic counseling in families with identified mutations and work in an interprofessional team approach to this rare condition for optimal patient care and clinical results. [Level 5]
References
Rogers M. Erythrokeratodermas: a classification in a state of flux? The Australasian journal of dermatology. 2005 Aug:46(3):127-41; quiz 142 [PubMed PMID: 16008642]
Macfarlane AW, Chapman SJ, Verbov JL. Is erythrokeratoderma one disorder? A clinical and ultrastructural study of two siblings. The British journal of dermatology. 1991 May:124(5):487-91 [PubMed PMID: 1828175]
Level 3 (low-level) evidencevan Steensel MA, Oranje AP, van der Schroeff JG, Wagner A, van Geel M. The missense mutation G12D in connexin30.3 can cause both erythrokeratodermia variabilis of Mendes da Costa and progressive symmetric erythrokeratodermia of Gottron. American journal of medical genetics. Part A. 2009 Feb 15:149A(4):657-61. doi: 10.1002/ajmg.a.32744. Epub [PubMed PMID: 19291775]
Level 3 (low-level) evidenceIshida-Yamamoto A. Erythrokeratodermia variabilis et progressiva. The Journal of dermatology. 2016 Mar:43(3):280-5. doi: 10.1111/1346-8138.13220. Epub [PubMed PMID: 26945536]
Richard G. Connexins: a connection with the skin. Experimental dermatology. 2000 Apr:9(2):77-96 [PubMed PMID: 10772382]
López-Bigas N, Olivé M, Rabionet R, Ben-David O, Martínez-Matos JA, Bravo O, Banchs I, Volpini V, Gasparini P, Avraham KB, Ferrer I, Arbonés ML, Estivill X. Connexin 31 (GJB3) is expressed in the peripheral and auditory nerves and causes neuropathy and hearing impairment. Human molecular genetics. 2001 Apr 15:10(9):947-52 [PubMed PMID: 11309368]
Level 3 (low-level) evidenceWhite TW, Bruzzone R. Multiple connexin proteins in single intercellular channels: connexin compatibility and functional consequences. Journal of bioenergetics and biomembranes. 1996 Aug:28(4):339-50 [PubMed PMID: 8844331]
Level 3 (low-level) evidenceLaird DW. Syndromic and non-syndromic disease-linked Cx43 mutations. FEBS letters. 2014 Apr 17:588(8):1339-48. doi: 10.1016/j.febslet.2013.12.022. Epub 2014 Jan 14 [PubMed PMID: 24434540]
Level 3 (low-level) evidenceGottfried I, Landau M, Glaser F, Di WL, Ophir J, Mevorah B, Ben-Tal N, Kelsell DP, Avraham KB. A mutation in GJB3 is associated with recessive erythrokeratodermia variabilis (EKV) and leads to defective trafficking of the connexin 31 protein. Human molecular genetics. 2002 May 15:11(11):1311-6 [PubMed PMID: 12019212]
Armstrong DK, Hutchinson TH, Walsh MY, McMillan JC. Autosomal recessive inheritance of erythrokeratoderma variabilis. Pediatric dermatology. 1997 Sep-Oct:14(5):355-8 [PubMed PMID: 9336804]
Level 3 (low-level) evidenceArita K, Akiyama M, Tsuji Y, Onozuka T, Shimizu H. Erythrokeratoderma variabilis without connexin 31 or connexin 30.3 gene mutation: immunohistological, ultrastructural and genetic studies. Acta dermato-venereologica. 2003:83(4):266-70 [PubMed PMID: 12926797]
Level 3 (low-level) evidenceCommon JE,O'Toole EA,Leigh IM,Thomas A,Griffiths WA,Venning V,Grabczynska S,Peris Z,Kansky A,Kelsell DP, Clinical and genetic heterogeneity of erythrokeratoderma variabilis. The Journal of investigative dermatology. 2005 Nov; [PubMed PMID: 16297190]
Hendrix JD Jr, Greer KE. Erythrokeratodermia variabilis present at birth: case report and review of the literature. Pediatric dermatology. 1995 Dec:12(4):351-4 [PubMed PMID: 8747585]
Level 3 (low-level) evidenceHohl D. Towards a better classification of erythrokeratodermias. The British journal of dermatology. 2000 Dec:143(6):1133-7 [PubMed PMID: 11122011]
Vandersteen PR, Muller SA. Erythrokeratodermia variabilis. An enzyme histochemical and ultrastructural study. Archives of dermatology. 1971 Apr:103(4):362-70 [PubMed PMID: 4326389]
Itin P, Levy CA, Sommacal-Schopf D, Schnyder UW. [Family study of erythrokeratodermia figurata variabilis]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 1992 Aug:43(8):500-4 [PubMed PMID: 1506216]
Landau M, Cohen-Bar-Dayan M, Hohl D, Ophir J, Wolf CR, Gat A, Mevorah B. Erythrokeratodermia variabilis with erythema gyratum repens-like lesions. Pediatric dermatology. 2002 Jul-Aug:19(4):285-92 [PubMed PMID: 12220269]
Level 3 (low-level) evidenceRajagopalan B, Pulimood S, George S, Jacob M. Erythrokeratoderma en cocardes. Clinical and experimental dermatology. 1999 May:24(3):173-4 [PubMed PMID: 10354172]
Level 3 (low-level) evidenceSingh N, Thappa DM. Erythrokeratoderma variabilis responding to low-dose isotretinoin. Pediatric dermatology. 2010 Jan-Feb:27(1):111-3. doi: 10.1111/j.1525-1470.2009.01044.x. Epub [PubMed PMID: 20199434]
Level 3 (low-level) evidence